Susceptibility of enteric pathogens to amoxicillin and clavulanate-potentiated amoxicillin.
Mégraud
F
F
Laboratoire de Bactériologie, Hôpital des Enfants, Bordeaux, France.
Gavinet
A
A
D000658:Amoxicillin / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002167:Campylobacter / Q000187:drug effects* / Q000302:isolation & purification; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000494:pharmacology*; D004359:Drug Therapy, Combination / Q000494:pharmacology; D004926:Escherichia coli / Q000187:drug effects; D006801:Humans; D007410:Intestinal Diseases / Q000382:microbiology; D008826:Microbial Sensitivity Tests; D012475:Salmonella / Q000187:drug effects* / Q000302:isolation & purification; D012760:Shigella / Q000187:drug effects* / Q000302:isolation & purification; D015008:Yersinia enterocolitica / Q000187:drug effects* / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D002969:Clavulanic Acids; D019818:Clavulanic Acid; D000658:Amoxicillin